JP2023549872A - ステロイド節約 - Google Patents

ステロイド節約 Download PDF

Info

Publication number
JP2023549872A
JP2023549872A JP2023529055A JP2023529055A JP2023549872A JP 2023549872 A JP2023549872 A JP 2023549872A JP 2023529055 A JP2023529055 A JP 2023529055A JP 2023529055 A JP2023529055 A JP 2023529055A JP 2023549872 A JP2023549872 A JP 2023549872A
Authority
JP
Japan
Prior art keywords
subject
treatment
sle
anifrolumab
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023529055A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549872A5 (enExample
Inventor
ホワイト，ウェンディ
グオ，シャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2023549872A publication Critical patent/JP2023549872A/ja
Publication of JP2023549872A5 publication Critical patent/JP2023549872A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023529055A 2020-11-18 2021-11-17 ステロイド節約 Pending JP2023549872A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063115286P 2020-11-18 2020-11-18
US63/115,286 2020-11-18
PCT/EP2021/081971 WO2022106460A2 (en) 2020-11-18 2021-11-17 Steroid sparing

Publications (2)

Publication Number Publication Date
JP2023549872A true JP2023549872A (ja) 2023-11-29
JP2023549872A5 JP2023549872A5 (enExample) 2024-07-29

Family

ID=78819991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023529055A Pending JP2023549872A (ja) 2020-11-18 2021-11-17 ステロイド節約

Country Status (10)

Country Link
US (1) US20240327529A1 (enExample)
EP (1) EP4247423A2 (enExample)
JP (1) JP2023549872A (enExample)
KR (1) KR20230110304A (enExample)
CN (1) CN116997359A (enExample)
AU (1) AU2021383537A1 (enExample)
CA (1) CA3200884A1 (enExample)
IL (1) IL302871A (enExample)
TW (1) TW202241945A (enExample)
WO (1) WO2022106460A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202300382T1 (it) * 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea
EP4616001A1 (en) * 2022-11-09 2025-09-17 Merck Patent GmbH Use of ifn-i activity as a biomarker for tlr inhibitor treatment
WO2025022280A1 (en) * 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
PE20090047A1 (es) 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
ES2643237T3 (es) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
AU2010323037B2 (en) 2009-11-30 2015-01-29 Biotest Ag Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE)
US20110281374A1 (en) * 2010-05-12 2011-11-17 Rainger George Edward Biomarker
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
EP3867645B1 (en) * 2018-10-18 2024-06-05 Oklahoma Medical Research Foundation Biomarkers for a systemic lupus erythematosus (sle) disease activity immune index that characterizes disease activity
DK4058060T3 (da) * 2019-11-11 2025-03-17 Astrazeneca Ab Type i-interferon-hæmning ved systemisk lupus erythematosus
JP2023527054A (ja) * 2020-05-29 2023-06-26 アストラゼネカ・アクチエボラーグ Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療
SMT202300382T1 (it) * 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LLORENTE, L. ET AL.: "Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic", ARTHRITIS AND RHEUMATISM, vol. 43, no. 8, JPN6025038149, 2000, pages 1790 - 1800, ISSN: 0005813000 *
MORAND, E. F. ET AL.: "Trial of Anifrolumab in Active Systemic Lupus Erythematosus", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 382, no. 3, JPN6025038148, 16 January 2020 (2020-01-16), pages 211 - 221, ISSN: 0005812999 *
TIAN, G. ET AL.: "Targeting IL-10 in auto-immune diseases", CELL BIOCHEMISTRY AND BIOPHYSICS, vol. 70, no. 1, JPN6025038150, 2014, pages 37 - 49, ISSN: 0005813001 *
國下 洋輔, 吉見 竜介: "インターフェロンシグネチャーを標的とした全身性エリテマトーデスの疾患活動性モニタリングと治療戦略", リウマチ科, vol. 第64巻, 第1号, JPN6025038146, July 2020 (2020-07-01), pages 92 - 98, ISSN: 0005812998 *

Also Published As

Publication number Publication date
EP4247423A2 (en) 2023-09-27
IL302871A (en) 2023-07-01
WO2022106460A9 (en) 2022-07-28
US20240327529A1 (en) 2024-10-03
WO2022106460A2 (en) 2022-05-27
CN116997359A (zh) 2023-11-03
CA3200884A1 (en) 2022-05-27
TW202241945A (zh) 2022-11-01
AU2021383537A1 (en) 2023-06-29
KR20230110304A (ko) 2023-07-21
WO2022106460A3 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
RU2527068C2 (ru) Фармакодинамические маркеры, индуцированные интерфероном альфа
JP2015504430A (ja) Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法
EP4058060B1 (en) Type i interferon inhibition in systemic lupus erythematosus
EP4306541A2 (en) Anti-ifnar1 dosing regime for subcutaneous injection
CN110831975A (zh) 用于治疗神经退行性疾病的cd14拮抗剂抗体
KR20110005783A (ko) 질환 마커 및 그의 용도
EP3191120B1 (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
KR20150010709A (ko) Il-17 길항제를 사용하는 강직성 척추염의 치료 방법
US20240327529A1 (en) Steroid sparing
JP2025169256A (ja) α４β７阻害薬及びＩＬ－２３阻害薬の併用療法
JP2023527054A (ja) Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療
US20220010007A1 (en) Treatment for Giant Cell Arteritis
WO2014100312A1 (en) Biomarkers for psoriasis treatment response
HK40080317B (en) Type i interferon inhibition in systemic lupus erythematosus
HK40080317A (en) Type i interferon inhibition in systemic lupus erythematosus
Kawanishi et al. Impact of anti-drug antibodies and neutralising antibodies on safety and efficacy of ozoralizumab in rheumatoid arthritis
EA046025B1 (ru) Подавление интерферона i типа при системной красной волчанке
KR20260013475A (ko) 루푸스의 치료
WO2020096664A1 (en) Treatment for giant cell arteritis

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250916

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260310